Related Experiment Video
Updated: Jun 4, 2025
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus
Win Min Han1,2, Sunil Solomon3, Laura Smeaton4
1The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Pathum Wan, Bangkok, Thailand.
Background:
Simplified approaches to hepatitis C virus (HCV) treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial.
Methods:
HCV RNA evaluations were scheduled at weeks 0, 24 (sustained viral response [SVR] visit), 48, and 72. Participants with post-entry HCV RNA ≥ lower limit of quantification (LLoQ) had deep sequencing of NS5A and NS5B genes performed. Phylogenetic analysis distinguished between reinfection and treatment failure. Reinfection rates per 100 person-years (PYS) were calculated with 95% confidence interval (CI) constructed using Poisson distribution.
Results:
Of 397 participants with post-entry HCV RNA, 29 had ≥LLoQ and available sequencing data. Of those 29, 5 participants initially designated as non-SVR, and 12 participants initially attaining SVR (evaluated at week 24) were determined to have reinfections (total 17 reinfections) (reinfection rate 3.9/100 PYS [95% CI, 2.4-6.2]). All 17 participants with HCV reinfection were male (13 MSM and 15 with HIV). Of 29 had ≥LLoQ, 12 were identified as treatment failure. SVR (excluding reinfections) in presence and absence of baseline RAS was 93.5% (43/46) and 97% (337/346), respectively, with an overall SVR rate of 97.0% [95% CI, 94.8-98.3] (385/397).
Conclusions:
Accounting for reinfections, SVR in MINMON was 97.0% further supporting simplified HCV treatment. No significant difference in SVR was found by baseline velpatasvir RAS. The high reinfection rate, especially among men who have sex with men (MSM) with human immunodeficiency virus (HIV), underscores the need to scale-up evidence-based interventions to reduce reinfection.
Clinical Trials Registration:
NCT03512210.
